Does the Angle of the Nail Matter for Pertrochanteric Fracture Reduction? Matching Nail Angle and Native Neck-Shaft Angle. Issue 4 (April 2018)

• Record Type: Journal Article
• Authors: Parry, Joshua A.; Barrett, Ian; Schoch, Bradley; Yuan, Brandon; Cass, Joseph; Cross, William
• Is Part Of: Journal of orthopaedic trauma. Volume 32:Issue 4(2018)
• Publication Date: 2018-04
• Subjects: hip fracture -- neck-shaft ankle -- cephalomedullary nails; Orthopedics -- Periodicals; Wounds and injuries -- Periodicals; Orthopedics -- Periodicals; Wounds and Injuries -- therapy -- Periodicals; Periodicals; 617.47044
• DOI: 10.1097/BOT.0000000000001096
• Languages: English
• ISSNs: 0890-5339

Abstract

Abstract : Objectives: To determine whether fixation of pertrochanteric hip fractures with cephalomedullary nails (CMNs) with a neck-shaft angle (NSA) less than the native NSA affects reduction and lag screw cutout. Design: Retrospective comparative study. Setting: Level I trauma center. Patients/Participants: Patients treated with a CMN for unstable pertrochanteric femur fractures (OTA/AO 31-A2.2 and 31-A2.3) between 2005 and 2014. Intervention: CMN fixation. Main Outcome Measurement: NSA reduction and lag screw cutout. Results: Patients fixed with a nail angle less than their native NSA were less likely to have good reductions [17% vs. 60%, 95% confidence interval (CI), −63% to −18%; P = 0.0005], secondary to more varus reductions (41% vs. 10%, 95% CI, 9%–46%; P = 0.01) and more fractures with ≥4 mm of displacement (63% vs. 35%, 95% CI, 3%–49%; P = 0.03). The cutout was not associated with the use of a nail angle less than the native NSA (60% vs. 76%, 95% CI, −56% to 18%; P = 0.5), varus reductions (60% vs. 32%, 95% CI, −13% to 62%; P = 0.3), or poor reductions (20% vs. 17%, 95% CI, −24% to 44%; P = 1.0). Conclusions: The fixation of unstable pertrochanteric hip fractures with a nail angle less than the native NSA was associated with more varus reductions and fracture displacement but did not affect the lag screw cutout. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.